Instrument Inactif

Autres langues Basilea Pharmaceutica AG Xetra

Actions

PK5

CH0011432447

Recherche biotechnologique et médicale

Temps réel estimé Tradegate 19:03:01 01/10/2026			Varia. 5j.	Varia. 1 janv.
72,35 ^EUR	0,00%		0,00%	-

14/09	Repli des actions japonaises face aux appels à ralentir le développement de l'IA ; le pétrole progresse	MT
14/09	Une filiale d'Asahi Kasei lance une étude de phase II sur l'antifongique Cresemba pour les patients pédiatriques au Japon	MT

Autres langues

14/09	Japanese Stocks Fall on AI Development Slowdown Calls; Oil Gains
14/09	Asahi Kasei Unit Starts Phase Two Study of Antifungal Cresemba for Pediatric Patients in Japan
14/09	Basilea-Partner Asahi Kasei startet Studie mit Pilzmittel bei Kindern
14/09	Basilea Pharmaceutica Partner Commences Antifungal Drug's Mid-stage Trial for Children in Japan
14/09	Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba(R) (isavuconazole) in pediatric patients
14/09	Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
14/09	Basileas Partner Asahi Kasei Therapeutics startet klinische Studie mit Antipilzmittel Cresemba® (Isavuconazol) bei Kindern in Japan
18/08	Basilea Pharmaceutica Ag Raises Earnings Guidance for the Full Year 2026
18/08	Swiss Market Index Closes Higher; Huber+Suhner Shares Drop
18/08	Aktien Schweiz gut behauptet - Defensive Index-Schwergewichte stützen
18/08	Aktien Schweiz: Nahostsorgen und höhere Zinsen bremsen den SMI
18/08	Basilea-Aktien nach Zahlen und erhöhtem Ausblick gesucht
18/08	Basilea Pharmaceutica AG Reports Earnings Results for the Half Year Ended June 30, 2026
18/08	Basilea schraubt nach erstem Semester Ziele hoch
18/08	Basilea Pharmaceutica Posts Higher H1 Net Profit, Total Revenue
18/08	Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
18/08	Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
18/08	Basilea erzielt starkes Halbjahresergebnis 2026 und erhöht die Finanzprognose für das Gesamtjahr; Phase-3-Programm mit Fosmanogepix auf Kurs
18/08	Swiss stocks - Factors to watch on August 18
05/08	Swiss Market Index Extends Rally; Sandoz Shares Gain
05/08	Basilea erhält weitere 5,4 Mio USD von BARDA für Antibiotika-Entwicklung
05/08	Basilea Pharmaceutica Bags Additional $5 Million Funding for Antibiotic Development
05/08	Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
05/08	Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
05/08	Basilea erhält zusätzliche USD 5.4 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam